Lilly Oncology Medical

🩺HCPs – Empower your #CLL patients to take an active role in their treatment journey. Share this infographic to guide them on best practices for effective communication and shared decision-making with their care team. ⬇️Download now: e.lilly/40c1BI4

CURRENTLY ENROLLING: A phase 2 clinical trial evaluating a CDK 4/6 inhibitor + temozolomide versus temozolomide monotherapy in children and young adults with newly diagnosed high-grade #Glioma. HCPs - Find trial and enrollment info here: e.lilly/40ae2UB #ClinicalTrials

SUNRAY-01 | CURRENTLY ENROLLING: A phase 3 trial investigating the addition of a #KRASG12C inhibitor to standard of care in patients w/ KRAS G12C-mutant advanced #NSCLC. For trial and enrollment information, click here: e.lilly/3QmoMdq #ClinicalTrials #LCSM #KRAS

Navigating #NSCLC care is complex—with more tests, treatments and the rise of #PrecisionMedicine, coordinated care is critical. Discover how molecular tumor boards support biomarker-driven decisions and optimize patient outcomes: e.lilly/45Bqccz #LCSM #BiomarkerTesting

Learn about SUNRAY-02, the first Ph3 trial investigating the addition of a #KRASG12C inhibitor to immunotherapy in early-stage & locally advanced #KRAS G12C-mutant #NSCLC. NOW ENROLLING | Find detailed trial & enrollment info here: e.lilly/3Gncfo6 #ClinicalTrials #LCSM

🔬Advances in #PrecisionMedicine underscore the importance of 🧬biomarker-informed care in #NSCLC. Learn how upfront NGS testing can provide the most comprehensive biomarker information, while also reducing overall cost and time to results: e.lilly/3FiWnDe #LCSM

We’re excited to be in New Orleans for the @SNM_MI Annual Meeting! Attendees, stop by booth 1315 to connect with the Lilly team and explore the research we’re presenting at this year’s meeting: e.lilly/3SVz4Cs #SNMMI25 #Radioligand #CancerResearch

PUBLISHED in @JCO_ASCO | BRUIN CLL-321: The first randomized study conducted exclusively in covalent BTKi pretreated #CLL/SLL, evaluating a non-covalent BTKi vs idelalisib/rituximab or bendamustine/rituximab. Full results and supplemental resources here: e.lilly/4kA96k4

#EHA2025 | Patient Reported Outcomes from BRUIN CLL-321: A randomized phase 3 study of a non-covalent BTKi vs idelalisib/rituximab or bendamustine/rituximab in #CLL/SLL patients previously treated w/ a covalent BTKi. Learn more here: e.lilly/3Ht38my #LeuSM #LymSM

#EHA2025 | Learn about real-world treatment patterns and outcomes for patients with #CLL following covalent BTKi discontinuation in Canada. View presentation details here: e.lilly/3ZliZcT #RealWorldData #RealWorldEvidence #LeuSM #LymSM

We’re excited to join the #hematology community at #EHA2025! Attendees, stop by booth A.06 to meet our medical team or click the link to learn more about the research we’re presenting: e.lilly/43XKvP4 #Leusm #Lymsm #CancerResearch

🩺Learn about the importance of tissue stewardship when implementing biomarker-informed care for patients w/ #NSCLC. 🧬 🔬These practices help ensure that tissue samples are handled & utilized optimally to support molecular testing & treatment selection: e.lilly/45ACFgG

At #ASCO25, we’re sharing initial results from a phase 1 study investigating a folate receptor alpha (FRα) targeting antibody-drug conjugate (#ADC) in patients w/ advanced #OvarianCancer and other solid tumors. 🔬 See the results here: e.lilly/4kleyHy #CancerResearch

At #ASCO25, read about the impact of body mass index (BMI) on efficacy and safety of a CDK 4/6 inhibitor in breast cancer patients treated in the phase III monarchE trial. See the analysis here: e.lilly/4joidD1 #BCSM #EarlyBreastCancer #CancerResearch

At #ASCO25, see analyses of the safety data from EMBER-3, a phase III study evaluating an oral #SERD as monotherapy and in combination with a CDK 4/6 inhibitor in ER+, HER2- advanced #BreastCancer. Learn more here: e.lilly/3SuulYf #BCSM #CancerResearch

#ASCO25 | Rapid Oral Presentation: 🔬🧬 Learn about the safety and efficacy of a #KRASG12C inhibitor + immunotherapy in first-line KRAS G12C-mutant advanced #NSCLC. See the data here: e.lilly/4jqDHiA #LCSM #CancerResearch

#ASCO25 - 🔬 See the results from the CAMPFIRE study, a phase 1/2 study investigating a VEGFR2 inhibitor in pediatric & young adult patients w/ relapsed/refractory desmoplastic small round cell tumor (DSRCT) or synovial sarcoma (SS). Learn more here: e.lilly/4jxuyoB

#ASCO25 | Learn about patient-reported outcomes (PROs) from EMBER-3, a phase 3 study investigating an oral #SERD with or without a CDK 4/6 inhibitor in ER+, HER2- advanced #BreastCancer. See the presentation details here: e.lilly/3ZIYg2K #BCSM #CancerResearch

🔬 At #ASCO25, we’re sharing efficacy and safety analyses of a second-generation #KRASG12C inhibitor in patients with KRAS G12C-mutant advanced colorectal cancer. View the presentation details here: e.lilly/43lo4EC #CRCsm #CancerResearch

We're excited to be back in Chicago for the @ASCO Annual Meeting and look forward to sharing new research from across our #oncology portfolio! 🔬🧬 🩺 Attendees, visit us at booth 19019 or click here to view our full lineup of #ASCO25 presentations: e.lilly/4mxpROd…